The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.
Antiepileptic Drugs in Non-Epilepsy Disorders: Relations between Mechanisms of Action and Clinical Efficacy
Abstract
Antiepileptic drugs (AEDs) are used extensively to treat multiple non-epilepsy disorders, both in neurology and psychiatry. This article provides a review of the clinical efficacy of AEDs in non-epilepsy disorders based on recently published preclinical and clinical studies, and attempts to relate this efficacy to the mechanism of action of AEDs and pathophysiological processes associated with the disorders. Some newer indications for AEDs have been established, while others are under investigation. The disorders where AEDs have been demonstrated to be of clinical importance include neurological disorders, such as essential tremor, neuropathic pain and migraine, and psychiatric disorders, including anxiety, schizophrenia and bipolar disorder. Many of the AEDs have various targets of action in the synapse and have several proposed relevant mechanisms of action in epilepsy and in other disorders. Pathophysiological processes disturb neuronal excitability by modulating ion channels, receptors and intracellular signalling pathways, and these are targets for the pharmacological action of various AEDs. Attention is focused on the glutamatergic and GABAergic synapses. In psychiatric conditions such as schizophrenia and bipolar disorder, AEDs such as valproate, carbamazepine and lamotrigine appear to have clear roles based on their effect on intracellular pathways. On the other hand, some AEDs, e.g. topiramate, have efficacy for nonpsychiatric disorders including migraine, possibly by enhancing GABAergic and reducing glutamatergic neurotransmission. AEDs that seem to enhance GABAergic neurotransmission, e.g. tiagabine, valproate, gabapentin and possibly levetiracetam, may have a role in treating neurological disorders such as essential tremor, or anxiety disorders. AEDs with effects on voltage-gated sodium or calcium channels may be advantageous in treating neuropathic pain, e.g. gabapentin, pregabalin, carbamazepine, oxcarbazepine, lamotrigine and valproate. Co-morbid conditions associated with epilepsy, such as mood disorders and migraine, may often respond to treatment with AEDs. Other possible disorders where AEDs may be of clinical importance include cancer, HIV infection, drug and alcohol abuse, and also in neuroprotection. A future challenge is to evaluate the second-generation AEDs in non-epilepsy disorders and to design clinical trials to study their effects in such disorders in paediatric patients. Differentiation between the main mechanisms of action of the AEDs needs more consideration in drug selection for tailored treatment of the various non-epilepsy disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While benzodiazepine use in autism is relatively uncommon, owing to concerns of behavioral disinhibition, some anticonvulsants that likely exert GABAergic effects are used for mood stabilization [262], and there is ongoing interest in the potential role of GABAergic treatments for catatonia in autism [263].”
From Consensus Paper: Pathological Role of the Cerebellum in Autism (2012) · cites this paper as [262]
Citations
Cites
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Göttlicher, M., Minucci, S., Zhu, P., Krämer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Coco, F. L., Nervi, C., Pelicci, P. G., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,930
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Algorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,337
The neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1430 · Cited by 1,243
Akbarian, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160008002 · Cited by 1,002
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
An astrocytic basis of epilepsy
Tian, G.-F., Azmi, H., Takano, T., Xu, Q., Peng, W., Lin, J., Oberheim, N., Lou, N., Wang, X., Zielke, H. R., et al. (2005) · Nature Medicine · doi:10.1038/nm1277 · Cited by 806
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Anticonvulsant drugs for management of pain: a systematic review
McQuay, H., Carroll, D., Jadad, A. R., Wiffen, P. J., & Moore, A. (1995) · BMJ · doi:10.1136/bmj.311.7012.1047 · Cited by 712
Research works printed but not linked: 14
- Lydiard, 2003, J Clin Psychiatry, 64, 21
- Nemeroff, 2003, Psychopharmacol Bull, 37, 133
- Kralic, 2005, J Clin Invest, 115, 584, 10.1172/JCI200523625 · DOI
- Chetcuti, 2005, Int J Neuropsychopharmacol, 28, 1
- Keck, 2005, JClin Psychiatry, 67, 8
- Premkumar, 2006, Cochrane Database Syst Rev, &NA;, CD005962
- Drake, 2001, Cephalalgia, 21, 373
- Krusz, 2001, Cephalalgia, 21, 373
- Keck, 1993, J Clin Psychiatry, 54, 305
- Manji, 2001, Psychopharmacol Bull, 35, 5
- Owens, 2003, Psychopharmacol Bull, 37, 17
- Henry, 2003, Psychopharmacol Bull, 37, 5
- Myrick, 2003, Prim Psychiatry, 10, 59
- De Paulis, 2003, Curr Opin Invest Drug, 4, 863
Cited by
Sorted by citations
Consensus Paper: Pathological Role of the Cerebellum in Autism
Fatemi, S. H., Aldinger, K. A., Ashwood, P., Bauman, M. L., Blaha, C. D., Blatt, G. J., Chauhan, A., Chauhan, V., Dager, S. R., Dickson, P. E., et al. (2012) · The Cerebellum · doi:10.1007/s12311-012-0355-9 · Cited by 723
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Swarm, R. A., Paice, J. A., Anghelescu, D. L., Are, M., Bruce, J. Y., Buga, S., Chwistek, M., Cleeland, C. S., Craig, D. S., Gafford, E. F., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0038 · Cited by 641
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 529
Antiepileptic drug interactions—Principles and clinical implications
I. Johannessen, S., & Johannessen Landmark, C. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246254 · Cited by 343
Swarm, R. A., Abernethy, A. P., Anghelescu, D. L., Benedetti, C., Blinderman, C. D., Boston, B., Cleeland, C. S., Coyle, N., deLeon-Casasola, O. A., Eilers, J., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0076 · Cited by 333
Metadata
- Authors
- Johannessen Landmark, C.
- Venue
- CNS Drugs
- Published
- 2008
- Volume
- 22
- Issue
- 1
- Pages
- 27-47
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2195324906
- Cited by
- 316
- References
- 157
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 11 · 2023: 15 · 2022: 9 · 2021: 7 · 2020: 5 · 2019: 17 · 2018: 10 · 2017: 10 · 2016: 22 · 2015: 15 · 2014: 18 · 2013: 27 · 2012: 28
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- antiepileptic drugs, off-label drug use, essential tremor, neuropathic pain, migraine, anxiety disorders, schizophrenia, bipolar disorder, GABAergic neurotransmission, glutamatergic neurotransmission, ion channels, valproic acid, carbamazepine, lamotrigine, topiramate, gabapentin, pregabalin, tiagabine, mood disorders, neuroprotection, second-generation antiepileptic drugs, drug selection
- MeSH terms
- Anticonvulsants, Anxiety, Mental Disorders, Bipolar Disorder, Humans, Migraine Disorders, Nervous System Diseases, Pain, Schizophrenia, Essential Tremor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
